jeudi 4 mai 2017

Onco Actu du 4 mai 2017

1. Biologie

At Last, a Clue to Where Cancer Metastases Are Born [Scripps Research Institute]

3.1.1 Tabac - e-cigs

Imperial Brands could launch heated tobacco product in months if needed [Reuters]

4.1 Dép., diag. & prono. - Prostate

Thousands of men with prostate cancer get risky treatment they don’t need. New approaches could curb that [STAT]

4.12 Biopsies liquides

Prostate cancer: Blood test could help target treatment [BBC News]

5.12.5 Immunothérapies - Pharma

Boehringer backs €20M Series A in checkpoint inhibitor startup [FierceBiotech]

5.2 Pharma

Genentech cancer R&D vet Raphaël Rousseau jumps ship, joins Gritstone [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

European Commission warns UK over drug authorisation validity due to Brexit [Pharmafile]

5.4 Traitements - Economie

Pricing furor aside, drug spending growth slowed last year—but still hit $323B [FierceBiotech]

NICE nod for Amgen’s rare leukaemia drug [PharmaTimes]

QuintilesIMS analysts forecast a wave of new drug approvals by ’22, dominated by cancer and orphan therapies [EndPoints]

U.S. prescription drug spending as high as $610 billion by 2021: report [Reuters]

5.6.4 ESMO - Poumon

ELCC 2017 Press Release: Patients With Non-Small-Cell Lung Cancer Respond Best to Salvage Chemotherapy When Pre-Treated With PD-1/PD-L1 Inhibitors [ESMO]

5.6.6 ESMO - Sein

IMPAKT 2017: Few Variations in Somatic Mutations Observed Between Pregnant and Non-Pregnant Patients with Breast Cancer [ESMO]

IMPAKT 2017: Luminal Androgen Receptor (LAR) Subtype of Triple Negative Breast Cancer (TNBC) Demonstrates In Vitro and In Vivo Sensitivity to CDK4/6 Inhibition [ESMO]

IMPAKT 2017: High Baseline TIL Levels Signal Superior Responses in HER2-Positive Breast Cancer [ESMO]

6. Lutte contre les cancers

WHO to help bring cheap biosimilar cancer drugs to poor [Reuters]

Urgent Care Services For Cancer Patients Offer A Gentler ER Alternative [NPR]

6.10 Politiques

Martin McKee: The infamous Brexit dinner party—health was a major issue, but only for the EU [BMJ Blogs]

6.10.1 Politiques (USA)

If Budget Holds, NIH Precision Study Could Be Flush As Volunteers Arrive [Xconomy]

6.11 Patients

Half of Breast Cancer Patients Pursue Reconstructive Surgery Without Understanding of Risks [OSUCCC]

6.5 Médecines alternatives

It’s full steam ahead for cancer quack Stanislaw Burzynski [Respectful Insolence]

6.7 DMP, Big Data & applis

An AI-Driven Genomics Company Is Turning to Drugs [MIT Technology Review]

6.7.3 DMP

‘Information blocking’ is a shameful practice in the electronic health record industry [STAT]

6.9 Controverses

Utah watchdog launches probe of Patrick Soon-Shiong’s controversial donation [STAT]